The popular anti-obesity drug sibutramine, marketed in India by a dozen companies under brand names such as Reductil, Meridia and Sibutrex, is likely to be banned.

The drug, prescribed worldwide for three decades, has been linked in research over the past few years with increased cardiovascular events like cardiac arrests and strokes.